Opportunity with Neoplasia journal – Commissioning Editor Oncology (call for applications)
8 Dec 2021
As a partner to ScienceDirect through the European Journal of Cancer (EORTC’s Official Journal), we are pleased to herewith share an exciting opportunity with one of the publisher’s other journals, Neoplasia.
Neoplasia – a peer-reviewed journal of the ScienceDirect family that publishes the results of novel investigations in all areas of oncology research – is currently recruiting for a Commissioning Editor in Oncology.
The role of the Commissioning Editor Oncology will be to attract key individuals as top authors to the journal.
Candidates for the role should have a scientific background in Cancer Research / Oncology (PhD minimum), a good understanding of related & interdisciplinary areas with a view of emerging topics, international connections within/across the scientific community, as well as strong networking capabilities and an interest in scientific publishing.
Deadline for applications is December 18, 2021.
For more information on expectations of the role and details of the application process, read on here.
Related News
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
11 Dec 2024
Minister F. Vandenbroucke visits EORTC Headquarters to strengthen collaborative efforts in clinical cancer research
21 Nov 2024
IMMUcan has completed patient enrolment
12 Nov 2024
EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients
5 Nov 2024
Pink October at EORTC: Over 60 years of impactful breast cancer research
29 Oct 2024
Spotlight on ENA 2024 News
25 Oct 2024
Do regulations and policies undermine the social value of independent academic research?
25 Oct 2024
EORTC Quality of Life Group’s participation to ISOQOL 2024
10 Oct 2024
New Insights into Glioblastoma Treatment for Older Adults Patients
8 Oct 2024
TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival
24 Sep 2024